ArticleTransboundary and emerging diseases2025
Discovery of a Structurally Stable Immunodominant Region in ASFV p30 C-Terminus Using a Panel of Monoclonal Antibodies.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is a lethal hemorrhagic viral disease of pigs with devastating global socioeconomic impacts. Due to the absence of a safe and effective vaccine, early surveillance and precise diagnostics are critical for ASF prevention and control. The ASF virus (ASFV) p30 protein, one of the most immunogenic early-expressed antigens during infection, is a prime target for diagnostic assays and subunit vaccines. Its comprehensive antigenic characterization remains crucial for rational vaccine design. In this study, we generated a panel of 20 monoclonal antibodies (MAbs) against the ASFV p30 protein, classifying them into 11 groups based on epitope specificity. MAbs from six groups (subgroups I-1, I-2, and II-1, as well as groups III, IV, and V, collectively comprising 15 MAbs) recognized six distinct epitopes within the C-terminus of p30 (137-194 aa), while MAb 16-5E7E8 (subgroup II-2) recognized a distinct epitope within residues 154-190. The p30 C-terminus (137-194 aa) demonstrated structural stability under denaturing conditions (SDS-PAGE and western blot [WB]) and was identified as an immunodominant region through its reactivity with ASFV-positive sera. Notably, MAbs targeting this immunodominant region exhibited modest neutralizing activity, whereas those binding to other regions showed no neutralizing activity. Furthermore, MAb Q4-1F10B7 (group VI) recognized a linear epitope "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.